| 注册
首页|期刊导航|临床与病理杂志|前列地尔在糖尿病肾病中的研究进展

前列地尔在糖尿病肾病中的研究进展

石冰青

临床与病理杂志2017,Vol.37Issue(12):2709-2716,8.
临床与病理杂志2017,Vol.37Issue(12):2709-2716,8.DOI:10.3978/j.issn.2095-6959.2017.12.033

前列地尔在糖尿病肾病中的研究进展

Research progress of alprostadil in diabetic nephropathy

石冰青1

作者信息

  • 1. 吉林大学第二医院肾内科,长春130000
  • 折叠

摘要

Abstract

Prostaglandin E1 (PGE1),a major component of prostaglandin injection,is a potent physiologically active substance with a wide range of physiological and pharmacological effects.It can be used to treat diabetic nephropathy (DN) through various mechnisims,such as inhibiting platelet aggregation,inhibiting inflammatory reaction and dilating renal vessels.It is effective and safe.The current study evidenced that alprostadil injection can be used alone,in sequential treatment or with other drugs.Any of these can reduce 24 h urinary proteinuria,serum creatinine,urinary albumin,blood urea nitrogen and other related indicators of DN,thus effectively improve renal function,and delay the progression of kidney disease,and it is more effective with early treatment.In addition,in the treatment ofDN,PGE1 have less adverse effect.Even for elderly patients (60 years of age),it is still safe with high clinical value.

关键词

前列地尔注射液/糖尿病肾病/尿蛋白

Key words

alprostadil injection/diabetic nephropathy/urinary protein

引用本文复制引用

石冰青..前列地尔在糖尿病肾病中的研究进展[J].临床与病理杂志,2017,37(12):2709-2716,8.

临床与病理杂志

OACSTPCD

1673-2588

访问量0
|
下载量0
段落导航相关论文